IP Library Granted Patent US 8,647,865
Granted Patent B2
US 8,647,865 · App. 13/734,560 · Granted Feb 11, 2014

Promiscuous PAP CD4 T cell epitopes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,647,865
App. No.
13/734,560
Granted
Feb 11, 2014
Kind
B2
Abstract

The present invention relates to the discovery of novel T cell epitopes of the human prostatic acid phosphatase (PAP) protein that is promiscuous for at least 15 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such an epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides.

Claims (10)

1. An isolated nucleic acid encoding a fusion polypeptide consisting of (1) a peptide consisting of 15 to 18 amino acids and comprising the amino acid sequence of SEQ ID NO:1, fused to (2) a heterologous peptide via a peptide bond.

2. The nucleic acid of claim 1 , wherein the peptide in (1) consists of the amino acid sequence of SEQ ID NO:1.

3. The nucleic acid of claim 1 , wherein the heterologous peptide is a granulocyte-macrophage colony-stimulating factor (GM-CSF).

4. The nucleic acid of claim 1 , wherein the fusion polypeptide is the peptide of SEQ ID NO:1 fused to a granulocyte-macrophage colony-stimulating factor (GM-CSF) via a peptide bond.

5. An expression cassette comprising the nucleic acid of claim 1 and directing the expression of a fusion polypeptide consisting of (1) a peptide consisting of 15 to 18 amino acids and comprising the amino acid sequence of SEQ ID NO:1, fused to (2) a heterologous peptide via a peptide bond.

6. The expression cassette of claim 5 , which is a recombinant viral vector.

7. The expression cassette of claim 5 , wherein the peptide in (1) consists of the amino acid sequence of SEQ ID NO:1.

8. The expression cassette of claim 5 , wherein the heterologous peptide is a granulocyte-macrophage colony-stimulating factor (GM-CSF).

9. The expression cassette of claim 5 , which directs the expression of a fusion polypeptide consisting of (1) a peptide consisting of the amino acid sequence of SEQ ID NO:1, fused to (2) a granulocyte-macrophage colony-stimulating factor (GM-CSF) via a peptide bond.

10. A host cell comprising the expression cassette of claim 5 .

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042389 FRAME: 505. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Feb 14, 2018
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 046088/0882 →
RELEASE OF SECURITY INTEREST Recorded Jul 5, 2017
From: BARCLAYS BANK PLC
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 043089/0288 →
CHANGE OF NAME Recorded May 3, 2017
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 042389/0505 →